AI Healthcare Regulations in West Virginia: A Comprehensive Guide

West Virginia has no AI-specific healthcare statutes as of mid-2025. Compliance involves layering federal frameworks (FDA, HIPAA, FTC) over existing WV medical practice, data privacy, and consumer protection laws.

Quick Answer: West Virginia AI Healthcare Regulations

West Virginia healthcare providers and AI developers operate under a regulatory environment built almost entirely on federal law. This is supplemented by general-purpose state statutes not specifically designed for AI.

No state legislation is dedicated solely to artificial intelligence in healthcare. West Virginia lacks an AI in Medicine Act, a state-level SaMD (Software as a Medical Device) registry, and published guidance from the West Virginia Board of Medicine on AI-assisted clinical decision-making. Instead, a patchwork of regulations exists: federal agency authority from the FDA, HIPAA's Office for Civil Rights, and the FTC. These are layered over West Virginia's medical practice act (W. Va. Code Ch. 30, Art. 3), its consumer protection statute (W. Va. Code Ch. 46A), and its data breach notification law (W. Va. Code Ch. 46A-2A-101 et seq.).

For a hospital system or startup deploying AI in WV:

• Federal clearance or approval of an AI tool does not end compliance obligations.
• Physician accountability under W. Va. Code Ch. 30, Art. 3 extends to AI output in the exam room.
• Patient data fed into any AI system triggers HIPAA's full technical and administrative safeguard requirements (45 CFR Parts 160, 162, and 164).
• Overstating AI capabilities exposes entities to FTC scrutiny under 15 U.S.C. § 41 et seq. and state consumer protection liability under W. Va. Code § 46A-6-101 et seq.

The West Virginia Legislature has not passed AI-specific healthcare bills as of this writing. However, federal regulatory activity is accelerating, and state-level proposals could follow quickly.

Federal Framework for AI in Healthcare Affecting West Virginia

FDA and Software as a Medical Device

The FDA is the primary federal regulator for AI tools that meet the definition of a medical device under the Federal Food, Drug, and Cosmetic Act (FD&C Act, 21 U.S.C. § 321 et seq.). Software meeting this definition, including AI/ML-based clinical decision support tools, falls under FDA jurisdiction regardless of the provider's location.

The FDA's 2021 AI/ML-Based Software as a Medical Device Action Plan and its guidance on Clinical Decision Support Software (CDS) distinguish between locked algorithms that produce a specific output and adaptive algorithms that retrain on new data. Providers in West Virginia using AI tools for diagnosis, triage, or treatment recommendations should confirm whether the tool has received FDA 510(k) clearance, De Novo authorization, or Premarket Approval (PMA). A 2026 study in the Journal of Cancer Policy (Litt H et al., PMID 42025919) found that FDA-authorized oncology AI/ML devices often have limited clinical evidence supporting their real-world use. This underscores the importance of vendor due diligence beyond regulatory clearance alone.

Non-device CDS software, meaning tools that display clinical references or help a clinician independently review the basis for a recommendation, may fall outside FDA device regulation under the 21st Century Cures Act. Consult the FDA's CDS guidance directly to determine which category a tool occupies.

HIPAA

Any AI system that processes, stores, or transmits protected health information (PHI) triggers HIPAA obligations under 45 CFR Parts 160, 162, and 164. This applies to covered entities (hospitals, clinics, insurers) and their business associates, including AI vendors. The Privacy Rule (45 CFR Part 164, Subpart E), Security Rule (45 CFR Part 164, Subpart C), and Breach Notification Rule all apply.

The HHS Office for Civil Rights (OCR) enforces HIPAA and has signaled interest in AI-related bias and discrimination issues. An AI system that systematically produces worse outcomes for a protected class of patients could attract OCR attention under both HIPAA and Section 1557 of the Affordable Care Act.

FTC

The Federal Trade Commission Act (15 U.S.C. § 41 et seq.) prohibits unfair or deceptive acts and practices. The FTC has taken enforcement action against companies making unsubstantiated claims about AI capabilities in health contexts. Marketing an AI diagnostic tool as more accurate than it is, or failing to disclose material limitations, creates FTC exposure for both developers and healthcare organizations that repeat those claims.

NIST AI Risk Management Framework

The NIST AI Risk Management Framework (AI RMF 1.0, published January 2023) is voluntary but increasingly referenced in vendor contracts, hospital accreditation discussions, and federal procurement. It provides a structured approach to identifying, measuring, and managing AI risk across four functions: Govern, Map, Measure, and Manage. West Virginia healthcare organizations adopting the NIST AI RMF signal to payers, regulators, and patients that they are taking AI governance seriously, even without a state mandate.

West Virginia's Specific Regulatory Stance on AI in Healthcare

Medical Practice Act and Physician Responsibility

West Virginia Code Chapter 30, Article 3 governs the practice of medicine in the state. It does not mention artificial intelligence. It establishes that licensed physicians are responsible for the clinical decisions they make, regardless of the tools they use. An AI-generated diagnosis or treatment recommendation does not transfer liability from the physician to the algorithm. The standard of care in West Virginia is what a reasonably competent physician would do under similar circumstances. Using an AI tool that a reasonable physician would not rely upon, or relying on AI output without appropriate clinical judgment, can constitute a deviation from that standard.

Physician assistants practicing under W. Va. Code Chapter 30, Article 3B and nurses under W. Va. Code Chapter 30, Article 7 face analogous accountability. Their respective practice acts require competent, supervised practice, and AI tools do not alter that baseline obligation.

West Virginia Board of Medicine

The West Virginia Board of Medicine (consult the Board directly at wvbom.wv.gov for current guidance) has not, as of this writing, issued a formal position statement or advisory opinion specifically addressing AI in clinical practice. Providers should monitor the Board's website for updates. In the absence of specific guidance, the Board's general authority to discipline licensees for unprofessional conduct or deviation from the standard of care applies fully to AI-assisted practice.

Data Breach Notification

West Virginia's Identity Theft Protection Act, W. Va. Code Chapter 46A-2A-101 et seq., requires businesses and government entities that own or license computerized personal information to notify affected West Virginia residents of a security breach. The statute defines "personal information" to include combinations of a person's name with financial account numbers, Social Security numbers, and similar identifiers. Medical information is covered when combined with identifying data.

Notification must be made "in the most expedient time possible and without unreasonable delay" following discovery of a breach (W. Va. Code § 46A-2A-102). The statute does not specify a fixed number of days, unlike some other states. For breaches affecting 1,000 or more West Virginia residents, the entity must also notify the West Virginia Attorney General. Consult the Attorney General's Consumer Protection Division for current reporting procedures, as administrative requirements can change.

Consumer Protection

West Virginia Code § 46A-6-101 et seq. prohibits unfair or deceptive acts or practices in trade or commerce. A healthcare organization or AI vendor that misrepresents the capabilities, accuracy, or safety of an AI tool to patients or referring providers could face liability under this statute. The West Virginia Attorney General has authority to investigate and bring actions under Chapter 46A.

Ethical and Legal Considerations for AI Deployment in WV Healthcare

AI Bias and Health Equity

West Virginia's patient population includes significant rural, elderly, and economically disadvantaged communities. AI models trained predominantly on data from urban academic medical centers may perform poorly on this population, producing systematically biased outputs. A 2026 study in Inquiry (Basu S et al., PMID 42012014) found systematic overemphasis of technology and equity performance claims in Medicaid managed care procurement across 32 states. This serves as a warning that vendor marketing language about equity should be verified against actual validation data.

Healthcare organizations in WV should require vendors to provide demographic breakdowns of model training data and validation performance across relevant subgroups before deployment.

Physician Oversight and the Human-in-the-Loop Principle

The American Medical Association's ethical guidelines for AI in healthcare (AMA Policy H-480.940 and related guidance) emphasize that AI should augment, not replace, physician judgment. This aligns directly with the accountability framework under W. Va. Code Ch. 30, Art. 3. Clinical workflows should be designed so that a licensed clinician reviews and approves AI-generated recommendations before they affect patient care. Automated AI outputs that trigger treatment without physician review create both patient safety risks and malpractice exposure.

Informed Consent

West Virginia has no statute requiring specific informed consent for AI use in diagnosis or treatment. However, general informed consent principles under West Virginia common law and medical ethics require that patients receive material information about their care. Whether AI involvement in a diagnostic process is "material" to a reasonable patient is an unsettled question in West Virginia courts. The prudent approach is to disclose AI use in consent forms and patient communications, particularly when AI plays a significant role in diagnosis or treatment planning.

Liability

West Virginia follows a modified comparative fault system. In an AI-related medical malpractice case, liability could be allocated among the treating physician, the hospital, and potentially the AI vendor, depending on the facts and applicable contract terms. No West Virginia appellate court has issued a published opinion specifically addressing AI malpractice liability as of this writing. General medical malpractice principles apply: duty, breach, causation, and damages. Providers should review indemnification clauses in AI vendor contracts carefully.

Transparency and Explainability